Branched Stent Grafts Market Size, Share and Growth Outlook, 2026

Branched Stent Grafts Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Branched Stent Grafts Market size is forecast to increase from $447.5 Million in 2026 to $816.1 Million in 2034 at a CAGR of 7.8% between 2026 and 2034.

The Branched Stent Grafts market report provides detailed analysis and outlook of Branched Stent Grafts segments including By Product Type (Aortic Branched Stent Grafts, Iliac Branched Stent Grafts, Patient-Specific, Off-the-Shelf Branched Grafts), By Application (Fenestrated Endovascular Aortic Repair, Branched Endovascular Aortic Repair, Thoracic Endovascular Aortic Repair, Chimney), By Indication (Thoracoabdominal Aortic Aneurysms, Pararenal & Juxtarenal Aortic Aneurysms, Iliac Artery Aneurysms, Aortic Dissections), By End-User (Hospitals, Specialty Cardiac & Vascular Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Branched Stent Grafts Industry Overview

Growing Adoption of Advanced Endovascular Solutions for Complex Aortic Disease

The branched stent grafts industry is experiencing significant technological advancement as physicians increasingly favor minimally invasive approaches for the treatment of complex aortic arch, thoracic aortic, and abdominal aortic diseases. Branched stent graft systems are specifically designed to maintain blood flow through critical branch vessels while enabling effective exclusion of aneurysms and other vascular pathologies. The market is benefiting from continuous innovation in device design, regulatory approvals, and clinical collaborations aimed at improving procedural precision, reducing surgical risks, and expanding treatment options for patients with anatomically challenging vascular conditions.

Regulatory Approvals Accelerating Commercial Expansion

Regulatory milestones continue to strengthen the competitive landscape of the branched stent grafts market. Artivion announced that the FDA granted Pre-Market Approval (PMA) for the NEXUS Aortic Arch System, an advanced branched endograft technology developed by Endospan. Following the approval, Artivion exercised its corporate option to acquire Endospan, expanding its portfolio of complex aortic endovascular intervention technologies. The approval of the NEXUS platform highlights increasing regulatory support for next-generation branched graft systems designed to address difficult aortic arch pathologies through less invasive treatment approaches.

Breakthrough Device Recognition Driving Innovation

Manufacturers continue to invest heavily in advanced branched stent graft architectures capable of addressing increasingly complex vascular anatomies. Shanghai MicroPort Endovascular MedTech (Endovastec™) received FDA Breakthrough Device Designation for its investigational Hector™ Multi-Branch Thoracic Stent Graft System. The device features a low-profile, modular design intended for minimally invasive reconstruction of complex aortic arch diseases while preserving blood flow through essential branch vessels. Breakthrough Device recognition underscores the growing clinical interest in technologies that can simplify endovascular procedures and improve outcomes for patients requiring sophisticated aortic repair interventions.

Collaborative Development Supporting Patient-Specific Repair Strategies

Strategic partnerships are playing an increasingly important role in advancing branched stent graft technology. Terumo Aortic and Bentley initiated a clinical collaboration in the United States to evaluate the combined use of the Fenestrated TREO device with the BeFlared FEVAR stent graft system. The collaboration is focused on developing standardized yet patient-specific treatment configurations for individuals requiring precise branch vessel revascularization during complex abdominal and thoracic aortic repair procedures. Such initiatives reflect the industry's broader movement toward customized endovascular solutions that improve anatomical compatibility, procedural efficiency, and long-term vascular outcomes.

Branched Stent Grafts Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Branched Stent Grafts market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Cook Medical, W. L. Gore & Associates, Inc., Medtronic plc, Terumo Corporation (Terumo Aortic), MicroPort Scientific Corporation, Becton, Dickinson and Company (BD), Endologix LLC, Getinge AB, JOTEC GmbH (CryoLife/Artivion), Lombard Medical. The Branched Stent Grafts market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Branched Stent Grafts industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Branched Stent Grafts Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Branched Stent Grafts companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Branched Stent Grafts markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Branched Stent Grafts Market Competitive Benchmarking and Company Analysis

Leading companies in Branched Stent Grafts industry include- Cook Medical, W. L. Gore & Associates, Inc., Medtronic plc, Terumo Corporation (Terumo Aortic), MicroPort Scientific Corporation, Becton, Dickinson and Company (BD), Endologix LLC, Getinge AB, JOTEC GmbH (CryoLife/Artivion), Lombard Medical. The Branched Stent Grafts market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Branched Stent Grafts Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Branched Stent Grafts market remains one of the strongest-performing segments in the country.
The US Branched Stent Grafts Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Branched Stent Grafts market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Branched Stent Grafts industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Branched Stent Grafts markets

Canada's strong Branched Stent Grafts sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Branched Stent Grafts market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Branched Stent Grafts Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Branched Stent Grafts market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Branched Stent Grafts population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Branched Stent Grafts industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Branched Stent Grafts market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Branched Stent Grafts sales through 2034

France Branched Stent Grafts companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Branched Stent Grafts Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Branched Stent Grafts distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Branched Stent Grafts Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Branched Stent Grafts market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Branched Stent Grafts industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Branched Stent Grafts industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Branched Stent Grafts Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Branched Stent Grafts market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Branched Stent Grafts market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Branched Stent Grafts Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Branched Stent Grafts Market Segmentation

By Product Type
Aortic Branched Stent Grafts
Iliac Branched Stent Grafts
Patient-Specific
Off-the-Shelf Branched Grafts
By Application
Fenestrated Endovascular Aortic Repair
Branched Endovascular Aortic Repair
Thoracic Endovascular Aortic Repair
Chimney
By Indication
Thoracoabdominal Aortic Aneurysms
Pararenal & Juxtarenal Aortic Aneurysms
Iliac Artery Aneurysms
Aortic Dissections
By End-User
Hospitals
Specialty Cardiac & Vascular Centers
Ambulatory Surgical Centers

Top Companies in Branched Stent Grafts Industry

Cook Medical
W. L. Gore & Associates, Inc.
Medtronic plc
Terumo Corporation (Terumo Aortic)
MicroPort Scientific Corporation
Becton, Dickinson and Company (BD)
Endologix LLC
Getinge AB
JOTEC GmbH (CryoLife/Artivion)
Lombard Medical

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025